VEGF gene and phenotype relation with Alzheimer's disease and mild cognitive impairment.

BACKGROUND The expression of vascular endothelial growth factor (VEGF) represents one potential mechanism whereby vascular and Alzheimer's disease (AD) pathologies are related. The authors investigated whether AD cases, especially those having a rapid cognitive decline, more commonly carried a functional promoter gene variant for VEGF (-2578C/A) and showed elevated plasma levels of Vegf. In addition, the authors investigated whether patterns of association also were found for mild cognitive impairment (MCI) and conversion from MCI to AD. METHODS Group 1 included 317 AD cases and 320 unaffected control subjects. Group 2 included 113 MCI patients and 130 control subjects. Plasma levels of Vegf were measured by chemiluminescence for a subset of group 1. Genotype determinations were made for all subjects. FINDINGS The VEGF AA genotype was associated with an increased risk of developing AD (OR = 1.616, p = 0.046). This genotype also was associated with an accelerated cognitive decline in APOE small epsilon4 positive patients with AD (AA vs. CC OR = 6.5, p = 0.04). The VEGF AA genotype was a risk factor for MCI (OR = 2.5, p = 0.037) and MCI conversion to AD in APOE small epsilon4+ (OR = 6.5, CI = 2.014-20.980; p = 0.002). Vegf plasma levels were higher in patients with AD than controls (230 pg/mL vs. 42 pg/mL), and were even higher in those patients with a fast cognitive decline and the APOE epsilon4 allele. INTERPRETATION Modulation of VEGF expression is a potential mechanism associated with the risk of developing AD and its clinical deterioration.

[1]  J. Rosenstein,et al.  Activation of Receptor-Mediated Angiogenesis and Signaling Pathways after VEGF Administration in Fetal Rat CNS Explants , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  G. Annoni,et al.  Apolipoprotein E and α-1-antichymotrypsin allele polymorphism in sporadic and familial Alzheimer's disease , 1999, Neuroscience Letters.

[3]  P. Zandi,et al.  Vascular Risk Factors for Incident Alzheimer Disease and Vascular Dementia: The Cache County Study , 2006, Alzheimer disease and associated disorders.

[4]  Coronary artery disease is associated with Alzheimer disease neuropathology in APOE4 carriers. , 2006, Neurology.

[5]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[6]  R. Doody,et al.  A method for estimating progression rates in Alzheimer disease. , 2001, Archives of neurology.

[7]  D. Galimberti,et al.  Vascular endothelial growth factor gene variability is associated with increased risk for AD , 2005, Annals of neurology.

[8]  W. Lukiw,et al.  Angiogenic signaling in Alzheimer's disease , 2004, Neuroreport.

[9]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[10]  P. Scheltens,et al.  Advances in the early detection of Alzheimer's disease , 2004, Nature Reviews Neuroscience.

[11]  J. Lambert,et al.  Association study of the vascular endothelial growth factor gene with the risk of developing Alzheimer's disease , 2006, Neurobiology of Aging.

[12]  J. LaManna,et al.  Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. , 1998, Brain research. Molecular brain research.

[13]  D. Harvey,et al.  Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia , 2004, Neurology.

[14]  B. Griffin,et al.  Association Between Apolipoprotein E Alleles and Calcific Valvular Heart Disease , 2003, Circulation.

[15]  P. Carmeliet,et al.  VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death , 2003, Nature Genetics.

[16]  B. Zlokovic.  Clearing amyloid through the blood–brain barrier , 2004, Journal of neurochemistry.

[17]  J. Touchon,et al.  Classification criteria for mild cognitive impairment , 2001, Neurology.

[18]  A. Hofman,et al.  Epidemiology of Alzheimer's disease. , 1992, Epidemiologic reviews.

[19]  V. Pravica,et al.  Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. , 1999, Human immunology.

[20]  Onofre Combarros,et al.  Case-control study of vascular endothelial growth factor (VEGF) genetic variability in Alzheimer's disease , 2006, Neuroscience Letters.

[21]  K. Jin,et al.  From angiogenesis to neuropathology , 2005, Nature.

[22]  Association of early‐onset Alzheimer's disease with an interleukin‐1α gene polymorphism , 2000, Annals of neurology.

[23]  Yong Song Gho,et al.  Co-accumulation of vascular endothelial growth factor with β-amyloid in the brain of patients with Alzheimer’s disease , 2004, Neurobiology of Aging.

[24]  Berislav V. Zlokovic,et al.  Neurovascular mechanisms of Alzheimer's neurodegeneration , 2005, Trends in Neurosciences.

[25]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[26]  J. C. Torre.  Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics , 2004, The Lancet Neurology.